Cabozantinib

(Cometriq)

Cabozantinib

Drug updated on 11/8/2023

Dosage FormCapsule (oral; 20 mg, 80 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients with progressive, metastatic medullary thyroid cancer.

Product Monograph / Prescribing Information

Document TitleYearSource
Cometriq (cabozantinib) Prescribing Information.2020Exelixis, Inc. Alameda, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines